Connection

YOCHAI BIRNBAUM to Cardiovascular Diseases

This is a "connection" page, showing publications YOCHAI BIRNBAUM has written about Cardiovascular Diseases.
Connection Strength

2.462
  1. When Is It Appropriate to Publish a Meta-Analysis in Cardiovascular Drugs and Therapy? Cardiovasc Drugs Ther. 2023 06; 37(3):599-601.
    View in: PubMed
    Score: 0.325
  2. Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers. Cardiovasc Drugs Ther. 2024 Feb; 38(1):181-189.
    View in: PubMed
    Score: 0.310
  3. What Should Be Done With the Asymptomatic Patient With Right Bundle Branch Block? J Am Heart Assoc. 2020 10 20; 9(19):e018987.
    View in: PubMed
    Score: 0.274
  4. Introduction and Vision. Cardiovasc Drugs Ther. 2020 02; 34(1):1-2.
    View in: PubMed
    Score: 0.263
  5. GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovasc Drugs Ther. 2018 02; 32(1):65-72.
    View in: PubMed
    Score: 0.229
  6. Electrocardiographic risk stratification of asymptomatic population without cardiovascular disease: Should we add the QRS-T angle? J Electrocardiol. 2017 Sep - Oct; 50(5):543-544.
    View in: PubMed
    Score: 0.219
  7. Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials. J Diabetes Complications. 2017 02; 31(2):291-294.
    View in: PubMed
    Score: 0.208
  8. Modulation of eicosanoid production and activity as a potential explanation for some of the pleiotropic effects of statins. Cardiology. 2010; 116(1):45-7.
    View in: PubMed
    Score: 0.134
  9. Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: clinical evidence and possible underlying mechanisms. Am Heart J. 2007 Aug; 154(2):391-402.
    View in: PubMed
    Score: 0.110
  10. The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame. J Cardiovasc Pharmacol Ther. 2007 Jun; 12(2):98-111.
    View in: PubMed
    Score: 0.109
  11. Understanding gastrointestinal bleeding in patients with cardiac disease: an interdisciplinary approach. Expert Rev Cardiovasc Ther. 2025 Apr-May; 23(5):197-207.
    View in: PubMed
    Score: 0.096
  12. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
    View in: PubMed
    Score: 0.075
  13. Highlights from Selected Cardiovascular Disease Prevention Studies Presented at the 2019 European Society of Cardiology Congress. Curr Atheroscler Rep. 2019 11 19; 21(12):46.
    View in: PubMed
    Score: 0.065
  14. GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies. Cardiovasc Drugs Ther. 2026 Apr; 40(2):779-793.
    View in: PubMed
    Score: 0.024
  15. Rapid screening of cardiac patients with a miniaturized hand-held ultrasound imager--comparisons with physical examination and conventional two-dimensional echocardiography. Clin Cardiol. 2004 Apr; 27(4):241-5.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.